Addiction is not a character flaw – it is now recognized as a chronic brain disease with the potential for both recovery and relapse, and we must treat it with the same skill and compassion with which we approach heart disease, diabetes, and cancer (2016 Surgeon General’s Report). It is the most severe manifestation of a substance use disorder (SUD), characterized by significant impairments in health, social function and control over substance use. Similar to other chronic brain diseases, addiction can and should be treated with medications alongside supportive therapy when appropriate.
Opiant Pharmaceuticals, Inc. is a specialty pharmaceutical company developing therapies to treat substance use disorders and drug overdose.
In response to this growing public health crisis, Opiant is developing a robust clinical pipeline of products to treat substance use disorders and drug overdose.
Opiant CEO Roger Crystal Testifies Before the President’s Commission
September 27, 2017 – Opiant CEO Dr. Roger Crystal testifies before the President’s Commission on Combating Drug Addiction and the Opioid Crisis.
Opiant CEO Roger Crystal on Fox Business Varney & Co.
October 10, 2018 – Opiant CEO Dr. Roger Crystal discusses teaming with HHS on new fentanyl overdose nasal spray.
Opiant CEO Roger Crystal on Fox Business Network’s “Mornings with Maria”
August 3, 2018 – Opiant CEO Dr. Roger Crystal discusses Narcan following singer Demi Lovato’s hospitalization.